HC Wainwright reaffirmed their buy rating on shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) in a report published on Tuesday morning. HC Wainwright currently has a $6.00 target price on the stock, down from their prior target price of $30.00.

Other research analysts have also issued reports about the stock. Robert W. Baird lowered shares of Nivalis Therapeutics from an outperform rating to a neutral rating and reduced their price target for the company from $29.00 to $3.00 in a research report on Tuesday. Stifel Nicolaus downgraded shares of Nivalis Therapeutics from a buy rating to a hold rating and dropped their price objective for the stock from $16.00 to $3.25 in a report on Tuesday. Cowen and Company downgraded shares of Nivalis Therapeutics from an outperform rating to a market perform rating in a report on Tuesday. Raymond James Financial Inc. downgraded shares of Nivalis Therapeutics from an outperform rating to a market perform rating in a report on Tuesday. Finally, Zacks Investment Research raised shares of Nivalis Therapeutics from a hold rating to a buy rating and set a $5.75 price objective for the company in a report on Saturday, November 5th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Nivalis Therapeutics has an average rating of Hold and an average target price of $9.00.

Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 2.57 on Tuesday. Nivalis Therapeutics has a one year low of $3.68 and a one year high of $9.45. The firm’s market capitalization is $39.95 million. The firm’s 50-day moving average price is $6.46 and its 200-day moving average price is $5.84.

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. On average, equities analysts forecast that Nivalis Therapeutics will post ($2.10) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2016/11/30/nivalis-therapeutics-inc-nvls-receives-buy-rating-from-hc-wainwright.html.

In other news, EVP David Malcom Rodman sold 5,820 shares of the company’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the completion of the transaction, the executive vice president now directly owns 18,056 shares of the company’s stock, valued at $143,725.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co bought a new position in shares of Nivalis Therapeutics during the second quarter valued at about $105,000. Bank of New York Mellon Corp boosted its position in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock valued at $134,000 after buying an additional 1,189 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of Nivalis Therapeutics during the third quarter valued at about $145,000. Endurant Capital Management LP boosted its position in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock valued at $694,000 after buying an additional 19,629 shares in the last quarter. Finally, Opaleye Management Inc. boosted its position in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $1,287,000 after buying an additional 160,000 shares in the last quarter. Institutional investors own 79.26% of the company’s stock.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.